Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2021-10-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Nyrada Quarterly Activities Report & Appendix 4C 9 pages 499.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and is dated 26 October 2021, covering the quarter ended 30 September 2021. It includes detailed operational updates on drug development programs, financial summaries, and an Appendix 4C cash flow report, which is a standard quarterly cash flow report required by the ASX Listing Rules. The document contains substantive financial data such as cash flows from operating, investing, and financing activities, cash position, and payments to related parties. It is not merely an announcement or a brief summary but a comprehensive quarterly report with financial statements and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-10-25 English
2021 AGM Letter to Shareholders and Proxy 12 pages 1.8MB
AGM Information Classification · 95% confidence The document is titled '2021 AGM Letter to Shareholders and Proxy' and contains detailed information about the Annual General Meeting (AGM) of Nyrada Inc, including the date, virtual meeting instructions, proxy voting details, resolutions to be voted on, and shareholder voting rights. It includes no financial statements or financial performance data but focuses on the meeting logistics, proxy forms, and shareholder instructions. The document is about the AGM materials shared with shareholders, not the results or minutes of the meeting, nor is it an announcement of the meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed AGM-related content, confirming the classification with high confidence.
2021-10-18 English
2021 AGM Notice of Meeting and Proxy 41 pages 3.7MB
AGM Information Classification · 100% confidence The document is titled '2021 AGM Notice of Meeting and Proxy' and contains detailed information about the Annual General Meeting (AGM) of Nyrada Inc, including the agenda, resolutions for re-election of directors, proxy forms, voting instructions, and explanatory statements. It explicitly states it is a Notice of Meeting for the 2021 AGM and includes proxy materials. There is no indication that this is the actual Annual Report or financial statements, but rather materials related to the AGM itself. The document length is substantial (15,000 characters), consistent with a full AGM notice and proxy statement. Therefore, the document fits the category of AGM Information (AGM-R).
2021-10-18 English
Presentation to ASX Small and Mid-Cap Conference 18 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is titled as a "Presentation to ASX Small and Mid-Cap Conference" and is dated 13 September 2021. It contains detailed information about the company's drug development programs, strategy, market opportunity, and scientific data, including study results and patent information. The content is structured as a corporate presentation intended for investors and the market, with forward-looking statements and program updates. There are no financial statements, audit opinions, or regulatory certifications present. The document is not an earnings release or an annual/interim report but rather a detailed investor presentation. Therefore, the document fits the category of an Investor Presentation (IP). The document length (10,686 characters) supports that it is a full presentation rather than a brief announcement or report publication notice.
2021-09-12 English
Updated Share Trading Policy 8 pages 330.0KB
Governance Information Classification · 95% confidence The document is titled 'Updated Share Trading Policy' and contains detailed information about insider trading laws, blackout periods for trading, and securities trading rules applicable to directors, senior executives, and other restricted persons. It is a policy document outlining internal rules and compliance requirements related to securities trading by company insiders. There is no financial data, earnings information, or report publication announcement. The content focuses on governance and compliance related to securities trading and insider information. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2021-09-02 English
Appendix 4G and Corporate Governance Statement 25 pages 719.2KB
Governance Information Classification · 95% confidence The document is titled 'Nyrada 2021 Appendix 4G and Corporate Governance Statement' and references ASX Listing Rules 4.7.3 and 4.10.3. It includes an Appendix 4G, which is a key to disclosures related to the ASX Corporate Governance Council Principles and Recommendations, and a Corporate Governance Statement. The document is dated 30 August 2021 and relates to the financial year ended 30 June 2021. The content focuses on corporate governance disclosures, compliance with ASX listing rules, and governance practices rather than financial results or operational data. It is not a full annual report, audit report, or interim report but rather a governance disclosure document required by the ASX. The document is substantive and not merely an announcement or a link to a report. Therefore, the most appropriate classification is Governance Information (CGR).
2021-08-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.